New FMI Report Explores Impact of COVID-19 Outbreak on HDL Cholesterol Kits Market
The
growth of the HDL cholesterol kits market can be attributed to the increasing
prevalence of atherosclerosis due to high cholesterol level, which favours the
demand for cholesterol testing. According to the latest research by FMI, the global HDL cholesterol kits market is
expected to be valued at US$ 790 Mn by the end of 2029. The HDL cholesterol kits market is expected to expand at a CAGR of 5.0%
during the forecast period 2019-2029.
The
increasing incidence of obesity and hyperlipidaemia among people is boosting
the need for cholesterol testing, which is driving the growth of the HDL
cholesterol kits market. The prevalence of obesity has increased from 33.7% in 2007-2008 to 39.7% in 2015-2016 among adults in the U.S.
The increasing prevalence of obesity also increases the risk of cardiovascular
disorders, high blood pressure, and hyperlipidaemia. Moreover, the prevalence
of hyperlipidaemia is high among the obese population. Nearly 60-70% of patients suffering from obesity have
hyperlipidaemia. Other factors, such as growing awareness programs for cholesterol
testing and growing cholesterol testing among diabetic patients, are also
propelling the growth of the HDL cholesterol kits market.
Rise of ‘Regular Health Check’ Trend Uplifts
Prospects in East Asia
Low
awareness in middle- and low-income countries about cholesterol testing and
other healthcare testing are also among the major factors that are expected to
hamper the growth of the HDL cholesterol kits market. There is low awareness
about diseases such as dyslipidaemia and hypercholesterolemia in middle-income
countries and rural areas. Moreover, the chances of errors and inaccuracy in
HDL cholesterol testing methods, such HDL cholesterol precipitating method, are
among factors expected to restrain the growth of the HDL cholesterol kits
market.
The
North America HDL cholesterol kits market gain a maximum value share in 2018.
However, the East Asia HDL cholesterol kits market expected to witness
prominent growth owing to the higher demand for cholesterol testing in
countries such as China and Japan. Developing countries, such as China and
India, represent a significant growth rate in the HDL cholesterol kits market
due to the growing adoption of regular healthcare testing. The Middle East
& Africa HDL cholesterol kits market is expected to witness a sluggish
growth rate as compared to other regions.
The
global HDL cholesterol kits market has been studied based on the product type
and end user. Based on the product type, the HDL cholesterol kits market has
been segmented into HDL cholesterol precipitating reagent kit, HDL cholesterol
direct reagent kit, and HDL and LDL/VLDL assay kit. The HDL and LDL/VLDL assay
kit product type segment is expected to hold a prominent share in the global
HDL cholesterol kits market. Based on end user, the HDL cholesterol kits market
has been segmented into hospitals, clinics, and diagnostic laboratories. In
terms of revenue, the hospitals segment of the HDL cholesterol kits market was
a significant market for HDL cholesterol kits in 2018.
Partnerships and Acquisitions Governing the
Competition Landscape
Some
of the key players operating in the HDL cholesterol kits market are Diazyme
Laboratories, Inc., Randox Laboratories Limited, Fujifilm Holding Corporation,
Thermo Fisher Scientific, Abcam plc., Merck KGaA, Abbott Laboratories, Danaher
Corporation (Beckman Coulter Inc.), PerkinElmer, Inc., and Hoffmann-La Roche
Ltd.
Players
in the HDL cholesterol kits market are focusing on partnerships and
acquisitions with regional and global players to increase their sales
worldwide. For instance, through the acquisition of Wako Pure Chemical,
Fujifilm Holding Corporation expand its presence in the life science and
chemical sectors. The manufacturers of HDL cholesterol kits are focusing on the
expansion of their presence in key markets such as the Asia Pacific, the Middle
East, and Europe through distribution agreements and the opening of new
manufacturing facilities. The manufacturers of HDL cholesterol kits are also
focusing on the development of point-of-care testing as it is more helpful and
convenient for making quicker decisions. Moreover, HDL cholesterol kits
industry stakeholders are focusing on the addition of direct reagent kits in
their product portfolios.
About Us
Future
Market Insights (FMI) is a leading market intelligence and consulting firm. We
deliver syndicated research reports, custom research reports and consulting
services which are personalized in nature. FMI delivers a complete packaged
solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights and an aerial view of the
competitive framework and future market trends.
Contact Us
Mr.
Abhishek Budholiya
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44 (0) 20 7692 8790
Sales: sales@futuremarketinsights.com
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44 (0) 20 7692 8790
Sales: sales@futuremarketinsights.com
Comments
Post a Comment